PCOS and PMOS weight management in NYC and Long Island

Condition-aware obesity care that keeps metabolic health, reproductive goals, and weight stigma in view.

Polycystic ovary syndrome was renamed polyendocrine metabolic ovarian syndrome, or PMOS, in 2026. Weight-management care can include lifestyle support, metabolic evaluation, metformin discussion, and anti-obesity medication when an adult independently meets the criteria and the safety review supports treatment.

Important distinction: Wegovy, Zepbound, Saxenda, and other GLP-1-based obesity medicines are not FDA approved to treat PMOS or PCOS itself. They may be considered for chronic weight management when the patient meets the medicine's general obesity indication and the clinician confirms safety.

What condition-aware weight management includes

PMOS is a multisystem endocrine and metabolic condition. Care should not be reduced to a number on the scale or an assumption about ovarian cysts.

Weight and treatment history

Review weight trajectory, prior programs, nutrition patterns, movement, sleep, stress, medicines, and what has or has not been sustainable.

Metabolic health

Review blood pressure, glucose or diabetes risk, lipids, liver-health questions, family history, and other weight-related conditions.

Reproductive goals

Discuss menstrual patterns, contraception, pregnancy timing, infertility care, and medicines that may conflict with those goals.

PMOS symptoms and diagnosis

Review the existing diagnosis and current symptoms; arrange appropriate testing or referral when the diagnosis or scope is uncertain.

Mental health and eating patterns

Screen for anxiety, depression, body-image distress, disordered eating, and support needs without assuming that every patient has the same experience.

Long-term plan

Choose monitoring, nutrition, activity, medication, primary care, women's health, and specialist coordination that can continue beyond the first prescription.

Medication options have different jobs

The right plan depends on the clinical target. A medicine used for metabolic features of PMOS is not automatically a substitute for an FDA-approved chronic weight-management medicine.

Metformin

The international guideline supports considering metformin for metabolic and anthropometric outcomes in adults with PCOS and higher BMI. It is not an FDA-approved weight-loss drug.

Semaglutide or liraglutide

The guideline says GLP-1 receptor agonists may be considered for higher weight under general obesity rules. Wegovy and Saxenda have weight-management indications; product and eligibility matter.

Tirzepatide

Zepbound is a dual GIP and GLP-1 receptor agonist approved for chronic weight management in eligible adults, not specifically for PMOS or PCOS.

Nutrition and activity

Lifestyle support remains part of care, while goals should be individualized, respectful, and valuable even when weight does not change quickly.

Women's health care

Irregular cycles, contraception, abnormal bleeding, pregnancy goals, and other gynecologic concerns may need a parallel women's-health plan.

Specialist referral

Complex endocrine disease, infertility treatment, eating disorders, pregnancy, or another concern may need endocrinology, gynecology, reproductive medicine, or behavioral-health care.

Safety and care boundaries

Do not use GLP-1-based obesity medication during pregnancy. Discuss effective contraception and pregnancy timing before treatment.
A personal or family history of medullary thyroid carcinoma or MEN 2 can rule out medicines with the relevant boxed warning.
Review pancreatitis, gallbladder disease, severe gastrointestinal symptoms, kidney risk from dehydration, diabetes medicines, planned procedures, and every current medication.
Eating disorders and disordered eating should be considered in PMOS or PCOS regardless of body size, especially during weight-management care.
Medication should not be presented as a fertility treatment, a cure for PMOS, or a guarantee of weight loss, menstrual regularity, or insurance coverage.

What happens during evaluation and follow-up

1. Intake and goals

Share the diagnosis, weight and treatment history, current medicines, symptoms, reproductive goals, and the outcome that matters most.

2. Clinical review

The clinician reviews health history, vital signs, relevant labs, contraindications, and whether another service or specialist should be involved.

3. Access planning

If medication is appropriate, the team reviews the labeled indication, health-plan requirements, pharmacy access, and a realistic follow-up schedule.

4. Monitoring

Follow-up reviews response, side effects, nutrition, hydration, muscle-preserving activity, metabolic markers, menstrual or pregnancy changes, and whether the plan should continue.

Start in NYC or Long Island

Book the existing medical weight-loss evaluation. The care team will confirm whether the first visit is virtual or in person and whether women's-health or specialist coordination is also needed.